Document is current

Article History

Accepted: 13 May 2024

First Online: 17 June 2024

Declarations

:

: The authors received no financial support for the research, authorship and/or publication of this article.

: Drug Science receives an unrestricted educational grant from a consortium of medical cannabis companies to further its mission, which is the pursuit of an unbiased and scientific assessment of drugs regardless of their regulatory class. All Drug Science committee members including the Chair, are unpaid by Drug Science for their effort and commitment to this organisation. Anne K. Schlag is a scientific advisor to Somai Pharmaceuticals and Evolve. None of the authors (Michael T. Lynskey, Hannah Thurgur, Alkyoni Athanasiou-Fragkouli, Anne K. Schlag, David J. Nutt) would benefit from the wider prescription of medical cannabis in any form.

: According to the National Health Service Health Research Authority, T21 is classified as research; however, based on the Medical Research Council decision tools, research ethics committee review and approval are not required.

: All individuals provide signed informed consent for their data to be used for research purposes.

: Not applicable.

: The data that support the findings of this study are available on reasonable request from the corresponding author. The data are not publicly available as they contain information that could compromise the privacy of research participants.

: Not applicable.

: The authors confirm contribution to the paper as follows: study conception and design: ML, AKS, DJN; data collection: ML, AA, AKS, DJN; analysis and interpretation of results: ML, AA; manuscript preparation and editing: ML, HT. All authors reviewed the results and approved the final version of the manuscript.